White Spot LesionPhase 2/3NCT05139966
Fluoride Controlled-release System for Initial Lesions of Caries
A Phase 2/3 study testing Mouthwash Product in people with White Spot Lesion, run by Federal University of Paraíba at 1 site in Brazil.
Trial summary
OBJECTIVE: To evaluate in vivo the efficacy of fluoride-containing dentifrice incorporated in a controlled-release system (F-CSL, patent pending) in the remineralization of white spot lesions of caries in caries-active individuals. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- White Spot Lesion
- What is being tested?
- Mouthwash Product
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 21 participants
- Where
- 1 siteBrazil
- Study dates
- 3 Aug 2017to 12 Dec 2018
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- residents of a city without water fluoridation program
Who cannot join
- The use of orthodontic appliances, smokers, treatment with fluoride products and / or the use of antimicrobial in the last 4 weeks, carious lesions, periodontal disease and dental sensitivity
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Eficácia de dentifrício Com Sistema de liberação Controlada de flúor Para remineralização de lesões Iniciais de cárie: Estudo clínico Randomizado.
OBJECTIVE: To evaluate in vivo the efficacy of fluoride-containing dentifrice incorporated in a controlled-release system (F-CSL, patent pending) in the remineralization of white spot lesions of caries in caries-active individuals. METHODS: A double-blind randomized clinical trial to evaluate the bioavailability of intraoral fluoride in biomarkers of exposure (biofilm and saliva) after the use of experimental toothpaste in the control of dental caries. The study will last three months. The participants of the study will be divided into three groups according to the dentifrice used. The sample will be selected randomly and composed of children and adolescents who seek the service of cariology of the UFPB. There will be participants of both sexes, preferably of the metropolitan region of João Pessoa in order to guarantee the low fluorine exposure by the water of supply. Intrabucal photographs will be obtained. Samples of saliva will be collected after 3 hours of the last meal. The benefits will be achieved by obtaining the reduction of the white spot area (mm2) plus the fact that all the children will be examined and will receive information on the treatment needs and forwading for the same.
Read the detailed description
Study Design:A randomized, triple-blind crossover clinical trial study was performed to evaluate the bioavailability of intraoral fluoride in biomarkers of exposure (biofilm and saliva) after the use of mouthwash with experimental fluoride for one week, with wash-out periods between them. The biofilm was collected 1 hour (h) and 12h after toothbrushing and the use of mouthwash, and saliva was collected 1h (T1 - T60 min) and 12h. The data was obtained by potentiometry (ion selective electrode) for fluoride in these samples. The pilot test was performed with three participants before the study begins.
Experimental mouthwashes:The participants were allocated randomly to use the following experimental mouthwashes: P - placebo (without F); 100% sodium fluoride (NaF) (225 ppm) - positive control; 50% nanoencapsulated fluoride (225 ppm, 50% free NaF + 50% nanoF); and 100% nanoF (225 ppm) (Savoy SA - São Paulo, Brazil). All mouthwashes were packed in similar containers and had the same color and flavor. They were coded by an independent investigator not involved in the trial.
A simple randomization was performed taking into account a cross design. The unit of randomization was "mouthwash", so all mouthwashes had the same chance of being selected. The design of the study was created for each participant and for each new one another draw was made.
Clinical stage:First, the participants were submitted to dental prophylaxis and scraping to remove all biofilm and dental calculus. They used a placebo mouthwash for 7 days. Then, the Whitford protocol was followed [17]. Briefly, the subjects were instructed to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study). On the seventh day, the subjects were instructed to brush only the occlusal surfaces, rinse the mouthwash 2 times and do not use dental floss, to allow biofilm accumulation. After going to bed, they abstained from eating or drinking anything except water, did not brush their teeth or use the mouthwash. The next morning, after 12 hours of last brushing and mouthwash, and fasting, the first samples of stimulated saliva and biofilm (upper and lower right hemi-arch) were collected. Then, the volunteers brushed the occlusal surfaces and rinsed 10 mL of the mouthwash for 1 min. Soon after, saliva samples were collected in the following times: t1, t5, t10, t15, t20, t30, t45 and t60 minutes. Later, 1 hour after the mouthwash, the biofilm samples (left side) were collected.
The stimulated saliva (chewing on a silicone) was collected for 2 min, posteriorly the saliva samples were centrifuged at 6,000 rpm for 10 minutes in order to separate the saliva debris. The biofilm was collected from all tooth surfaces, in both buccal and lingual areas, using a 3S hollenback spatula, from which the samples were immediately transferred to an eppendorff tube, centrifuged, subsequently dried at 60 °C for 4 h and then weighed.
Determination of the concentration of fluoride:The samples were analyzed by the hexamethyldisiloxane (HMDS) facilitated diffusion method of Taves [21] modified by Whitford [22]. The analyzes were performed with a fluoride specific electrode (model 9409; Orion Research) and a potentiometer (model EA 940; Orion Research, Cambridge, MA, USA) (Model 720 A Orion). Fluoride standards (1-100 nM) were used to prepare calibration curves.
Statistical analysis:Statistical analysis were performed in software R considering α = 0.05. The Shapiro-Wilk and Kolmogorov Smirnov tests were applied to evaluate the normality of the data. The comparisons of F concentration in saliva and biofilm between groups were performed by repeated measures ANOVA after the Bonferroni test. The AUC measure (area below the curve) was calculated to indicate the efficacy of F retention in the saliva over the long term by taking the F concentration values in the time interval from 12h to 60 min after the last rinse. The relationship between fluoride concentrations in biofilm and saliva was determined using Spearman's correlation coefficient. The data was calculated on Graph Pad Prism (version 6) and Statistical Package (SPSS) version 23.
- Conditions
- White Spot Lesion
- Being tested
- Mouthwash Product
- Keywords
- fluorine, dental plaque, Toothbrushing
- Medical subject headings
- Dental Plaque
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mouthwash ProductDrug
Also called nano fluoride
The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
| Study group | Role | What they receive |
|---|---|---|
| G0 - placebo | Placebo comparator | All placebo mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, NO FLUORIDE WAS INCORPORATED. Receives: Drug: Mouthwash Product |
| G1: 100% - sodium fluoride (100% free NaF) | Experimental | These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm NaF (SODIUM FLUORIDE) WAS INCORPORATED. Receives: Drug: Mouthwash Product |
| G2: 50% nano fluoride (225 ppm, 50% free NaF + 50% nanoF) | Experimental | These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm (50% free NaF + 50% nanoF) WAS INCORPORATED. Receives: Drug: Mouthwash Product |
| G3: 100% nano fluoride (225 ppm) | Experimental | These mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm (100% nanoF) WAS INCORPORATED. Receives: Drug: Mouthwash Product |
What is being measured
The primary outcome is the main question the study is designed to answer.
levels of fluoride concentration in saliva and biofilm
It is expected that a concentration of fluoride would differ according to the type of formulation providing beneficial support in remineralization of the tooth enamel and preventing carious lesions.
Measured: 12 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2021
- Study start3 Aug 2017
- Primary completion12 Sep 2018
- Study completion12 Dec 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for White Spot LesionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- A randomized, triple-blind crossover clinical trial study was performed to evaluate the bioavailability of intraoral fluoride in biomarkers of exposure (biofilm and saliva) after the use of mouthwash with experimental fluoride for one week, with wash-out periods between them
- Masking
- Single blind
- Who is masked
- Care provider
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Federal University of Paraíba
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Fabio Correia Sampaio, Federal University of Paraíba
- Investigators
- FABIO C SAMPAIO, PhD, Principal investigator, Hospital Universitário Lauro Wanderley
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05139966
- Sponsor's protocol ID
- NaFnano brushing
- Status last verified
- Nov 2021
- First submitted
- 18 Nov 2021
- Last updated
- 1 Dec 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Dec 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Eficácia de dentifrício Com Sistema de liberação Controlada de flúor Para remineralização de lesões Iniciais de cárie: Estudo clínico Randomizado.
- ClinicalTrials.gov ID
- NCT05139966
- Acronym / sponsor ID
- NaFnano brushing
- Conditions
- White Spot Lesion
- Keywords
- fluorine, dental plaque, Toothbrushing
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- Federal University of ParaíbaUniversity, hospital or other
- Study start
- 3 Aug 2017 (actual)
- Primary completion
- 12 Sep 2018 (actual)
- Study completion
- 12 Dec 2018 (actual)
- First posted
- 1 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
OBJECTIVE: To evaluate in vivo the efficacy of fluoride-containing dentifrice incorporated in a controlled-release system (F-CSL, patent pending) in the remineralization of white spot lesions of caries in caries-active individuals. METHODS: A double-blind randomized clinical trial to evaluate the bioavailability of intraoral fluoride in biomarkers of exposure (biofilm and saliva) after the use of experimental toothpaste in the control of dental caries. The study will last three months. The participants of the study will be divided into three groups according to the dentifrice used. The sample will be selected randomly and composed of children and adolescents who seek the service of cariology of the UFPB. There will be participants of both sexes, preferably of the metropolitan region of João Pessoa in order to guarantee the low fluorine exposure by the water of supply. Intrabucal photographs will be obtained. Samples of saliva will be collected after 3 hours of the last meal. The benefits will be achieved by obtaining the reduction of the white spot area (mm2) plus the fact that all the children will be examined and will receive information on the treatment needs and forwading for the same.
Detailed description
Study Design:A randomized, triple-blind crossover clinical trial study was performed to evaluate the bioavailability of intraoral fluoride in biomarkers of exposure (biofilm and saliva) after the use of mouthwash with experimental fluoride for one week, with wash-out periods between them. The biofilm was collected 1 hour (h) and 12h after toothbrushing and the use of mouthwash, and saliva was collected 1h (T1 - T60 min) and 12h. The data was obtained by potentiometry (ion selective electrode) for fluoride in these samples. The pilot test was performed with three participants before the study begins.
Experimental mouthwashes:The participants were allocated randomly to use the following experimental mouthwashes: P - placebo (without F); 100% sodium fluoride (NaF) (225 ppm) - positive control; 50% nanoencapsulated fluoride (225 ppm, 50% free NaF + 50% nanoF); and 100% nanoF (225 ppm) (Savoy SA - São Paulo, Brazil). All mouthwashes were packed in similar containers and had the same color and flavor. They were coded by an independent investigator not involved in the trial.
A simple randomization was performed taking into account a cross design. The unit of randomization was "mouthwash", so all mouthwashes had the same chance of being selected. The design of the study was created for each participant and for each new one another draw was made.
Clinical stage:First, the participants were submitted to dental prophylaxis and scraping to remove all biofilm and dental calculus. They used a placebo mouthwash for 7 days. Then, the Whitford protocol was followed [17]. Briefly, the subjects were instructed to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study). On the seventh day, the subjects were instructed to brush only the occlusal surfaces, rinse the mouthwash 2 times and do not use dental floss, to allow biofilm accumulation. After going to bed, they abstained from eating or drinking anything except water, did not brush their teeth or use the mouthwash. The next morning, after 12 hours of last brushing and mouthwash, and fasting, the first samples of stimulated saliva and biofilm (upper and lower right hemi-arch) were collected. Then, the volunteers brushed the occlusal surfaces and rinsed 10 mL of the mouthwash for 1 min. Soon after, saliva samples were collected in the following times: t1, t5, t10, t15, t20, t30, t45 and t60 minutes. Later, 1 hour after the mouthwash, the biofilm samples (left side) were collected.
The stimulated saliva (chewing on a silicone) was collected for 2 min, posteriorly the saliva samples were centrifuged at 6,000 rpm for 10 minutes in order to separate the saliva debris. The biofilm was collected from all tooth surfaces, in both buccal and lingual areas, using a 3S hollenback spatula, from which the samples were immediately transferred to an eppendorff tube, centrifuged, subsequently dried at 60 °C for 4 h and then weighed.
Determination of the concentration of fluoride:The samples were analyzed by the hexamethyldisiloxane (HMDS) facilitated diffusion method of Taves [21] modified by Whitford [22]. The analyzes were performed with a fluoride specific electrode (model 9409; Orion Research) and a potentiometer (model EA 940; Orion Research, Cambridge, MA, USA) (Model 720 A Orion). Fluoride standards (1-100 nM) were used to prepare calibration curves.
Statistical analysis:Statistical analysis were performed in software R considering α = 0.05. The Shapiro-Wilk and Kolmogorov Smirnov tests were applied to evaluate the normality of the data. The comparisons of F concentration in saliva and biofilm between groups were performed by repeated measures ANOVA after the Bonferroni test. The AUC measure (area below the curve) was calculated to indicate the efficacy of F retention in the saliva over the long term by taking the F concentration values in the time interval from 12h to 60 min after the last rinse. The relationship between fluoride concentrations in biofilm and saliva was determined using Spearman's correlation coefficient. The data was calculated on Graph Pad Prism (version 6) and Statistical Package (SPSS) version 23.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (care provider)
- Number of arms
- 4
- Model description
- A randomized, triple-blind crossover clinical trial study was performed to evaluate the bioavailability of intraoral fluoride in biomarkers of exposure (biofilm and saliva) after the use of mouthwash with experimental fluoride for one week, with wash-out periods between them
| Arm | Type | Receives |
|---|---|---|
| G0 - placebo | Placebo comparator | Drug: Mouthwash ProductAll placebo mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, NO FLUORIDE WAS INCORPORATED. |
| G1: 100% - sodium fluoride (100% free NaF) | Experimental | Drug: Mouthwash ProductThese mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm NaF (SODIUM FLUORIDE) WAS INCORPORATED. |
| G2: 50% nano fluoride (225 ppm, 50% free NaF + 50% nanoF) | Experimental | Drug: Mouthwash ProductThese mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm (50% free NaF + 50% nanoF) WAS INCORPORATED. |
| G3: 100% nano fluoride (225 ppm) | Experimental | Drug: Mouthwash ProductThese mouthwashes were formulated with the following common ingredients: WATER (AQUA), POLYSORBATE 80, HYDROXYPROPYL GUAR,,SODIUM BENZOATE, POTASSIUM SORBATE. Finally, 225 ppm (100% nanoF) WAS INCORPORATED. |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- residents of a city without water fluoridation program
Key exclusion criteria (1 listed)
- The use of orthodontic appliances, smokers, treatment with fluoride products and / or the use of antimicrobial in the last 4 weeks, carious lesions, periodontal disease and dental sensitivity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mouthwash ProductAlso: nano fluorideThe participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study). | Drug | G0 - placebo, G1: 100% - sodium fluoride (100% free NaF), G2: 50% nano fluoride (225 ppm, 50% free NaF + 50% nanoF), G3: 100% nano fluoride (225 ppm) |
Primary outcome
levels of fluoride concentration in saliva and biofilm
Time frame: 12 hours
It is expected that a concentration of fluoride would differ according to the type of formulation providing beneficial support in remineralization of the tooth enamel and preventing carious lesions.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Dec 2021.
Related trials for White Spot Lesion
Not yet recruitingObservational study
Artificial Intelligence Versus Clinical Examination in White Spot Lesions Detection, Identification, And Scoring
White Spot Lesion of Tooth
Recruiting
EFFICACY OF BIOMIN FLUORIDE VERSUS SODIUM FLUORIDE VARNISHES, WITH AND WITHOUT DIODE LASER ON WHITE SPOT LESIONS REMINERALIZATION IN PRIMARY TEETH.
White Spot Lesions [Initial Caries] on Smooth Surface of Tooth
Not yet recruiting
S-PRG Filler for Preventing White Spot Lesions During Orthodontic Treatment
White Spot Lesion of Tooth, Orthodontic Treatment
Recruiting
Clinical Investigation of the Performance of Epinamel for Dental White Spot Lesions
White Spot Lesions [Initial Caries] on Smooth Surface of Tooth
Not yet recruiting
Clinical Outcomes, Cost-Effectiveness and Patient Satisfaction of Two Resin Infiltration Systems for The Management of White Spot Lesions
White Spot Lesion of Tooth
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
FABIO C SAMPAIO, PhD principal investigator
Hospital Universitário Lauro Wanderley
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Mouthwash Product in people with White Spot Lesion, run by Federal University of Paraíba at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Dec 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
levels of fluoride concentration in saliva and biofilm (time frame: 12 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Dec 2021.